Skip to main content

John P. Condon

Of Counsel

[email protected]

+1.617.348.4453

Share:

John’s practice focuses on corporate and securities law matters, with emphasis on the biotechnology, medical device and technology industries.

John represents companies in structuring, preparing for and completing initial public offerings, reverse merger transactions, follow-on offerings, ATM offerings and PIPEs. John also represents underwriters in capital markets transactions. In addition, John serves as outside corporate and securities counsel to public companies and advises on a broad range of corporate governance and securities compliance matters, including SEC requirements, Nasdaq and NYSE listing rules and proxy advisory firm policies.

John also advises entrepreneurs of early stage companies on formation, capital raising transactions and corporate governance matters, including through his involvement with the Massachusetts Medical Device Development Center (M2D2).

Prior to becoming an attorney, John worked as a legal assistant in the Securities Litigation Practice at Mintz Levin. He also interned at the Boston College Legal Assistance Bureau, the Massachusetts Clients’ Security Board of the Supreme Judicial Court, the Massachusetts Attorney General’s Office, and the U.S. Senate Committee on the Judiciary.

Education

  • Boston College (JD)
  • Middlebury College (BA)

Involvement

  • Advisory Board, The Massachusetts Medical Device Development Center (M2D2)
  • Contributor, Securities Matters blog
  • Mentor, including for the M2D2 $200K Challenge and MIT $100K Pitch Contest
  • Associate Lay Leader, Past Chair of Church Council, Sudbury United Methodist Church
  • Member, Boston Bar Association

Recent Insights

News & Press

Viewpoints

Public companies will soon be required to include an active hyperlink to each exhibit to all registration statements filed under the Securities Act of 1933, as amended, and all periodic and current reports filed under the Securities Exchange Act of 1934, as amended, filed on or after September 1, 2017.

News & Press

Mintz represented G1 Therapeutics, Inc. in its initial public offering of 7,781,564 shares of common stock. G1 Therapeutics is a clinical-stage biopharmaceutical company.
Mint has been named an official gold sponsor of the MIT 100K Entrepreneurship Competition. The event is a launch pad for students and researchers in the MIT community to act on their talent, ideas, and energy to produce tomorrow’s leading ventures.

Events